LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 76th Regular Session
May 11, 1999
TO: Honorable Bill Ratliff, Chair, Senate Committee on Finance
FROM: John Keel, Director, Legislative Budget Board
IN RE: HB2372 by Gutierrez (relating to exempting certain drugs,
medicines, and medical devices from the sales tax), As
Engrossed
**************************************************************************
* Estimated Two-year Net Impact to General Revenue Related Fundsfor *
* HB2372, As Engrossed: a negative impact of $(255,286,000) through *
* the biennium ending August 31, 2001, if the effective date is July *
* 1, 1999; and a negative impact of $(225,921,000) through the *
* biennium ending August 31, 2001, if the effective date is October *
* 1, 1999. *
**************************************************************************
The following table assumes an effective date of July 1, 1999.
All Funds, Five-Year Impact:
***************************************************************************
*Fiscal Probable Probable Probable Probable *
* Year Revenue Revenue Revenue Revenue *
* Gain/(Loss) to Gain/(Loss) to Gain/(Loss) to Gain/(Loss) to *
* General Revenue Cities Transit Counties/SPDs *
* Fund Authorities *
* 0001 *
* 1999 $(9,471,000) $0 $0 $0 *
* 2000 (119,362,000) (20,819,000) (8,175,000) (2,521,000) *
* 2001 (126,453,000) (22,056,000) (8,661,000) (2,671,000) *
* 2002 (134,295,000) (23,424,000) (9,198,000) (2,836,000) *
* 2003 (142,499,000) (24,855,000) (9,760,000) (3,010,000) *
* 2004 (150,966,000) (26,331,000) (10,340,000) (3,188,000) *
***************************************************************************
The following table assumes an effective date of October 1, 1999.
***************************************************************************
*Fiscal Probable Probable Probable Probable *
* Year Revenue Revenue Revenue Revenue *
* Gain/(Loss) to Gain/(Loss) to Gain/(Loss) to Gain/(Loss) to *
* General Revenue Cities Transit Counties/SPDs *
* Fund Authorities *
* 0001 *
* 2000 $(99,468,000) $(15,614,000) $(6,131,000) $(1,891,000) *
* 2001 (126,453,000) (22,056,000) (8,661,000) (2,671,000) *
* 2002 (134,295,000) (23,424,000) (9,198,000) (2,836,000) *
* 2003 (142,499,000) (24,855,000) (9,760,000) (3,010,000) *
* 2004 (150,966,000) (26,331,000) (10,340,000) (3,188,000) *
***************************************************************************
Fiscal Analysis
The bill would amend the Tax Code to exempt certain non-prescription
drugs and blood glucose monitoring test strips from the sales tax.
The governing body of a local taxing authority that imposes a local sales
and use tax could repeal the proposed exemption under certain
circumstances.
Methodology
Texas-specific non-prescription drug sales data were obtained from the
U.S. Census Bureau. The data were multiplied by the state sales tax rate
and extrapolated through fiscal 2004.
The fiscal impact is based on the assumption that no local taxing
authorities would repeal the exemption. To the extent that one or more
would repeal the exemption, the negative fiscal effects would be
reduced.
Local Government Impact
Local units of government would have a corresponding fiscal impact from
sales tax revenues, as indicated in the tables above.
Source Agencies:
LBB Staff: JK, BB, SM